By InvitationNot Applicable

CBM588 Reduces Colorectal Polyp Recurrence

Taiwan500 participantsStarted 2017-03-10

Plain-language summary

The goal of this randomized crossover clinical trial is to evaluate the efficacy of Clostridium butyricum MIYAIRI 588 (CBM588) in reducing colorectal adenomatous polyp recurrence in adult patients with a history of colorectal polyps. The main questions it aims to answer are: * Does CBM588 reduce the recurrence of colorectal adenomatous polyps? * Does CBM588 lead to a sustained decrease in polyp burden over time? Researchers will compare a group receiving CBM588 in the first year to a group receiving CBM588 in the second year (after a washout period) to determine whether CBM588 effectively lowers polyp recurrence rates and adenoma prevalence.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults with a history of colorectal adenomas that had been completely removed by endoscopic resection within the past three years, and who presented with recurrent colorectal polyps detected during surveillance colonoscopy * Willingness to undergo follow-up colonoscopies at study intervals * No antibiotic or probiotic use for at least three months before study entry * Written informed consent obtained Exclusion Criteria: * History of colorectal cancer or other gastrointestinal malignancies * Diagnosis of inflammatory bowel disease or familial adenomatous polyposis * Use of antibiotics and other probiotics during the study period

What they're measuring

Colorectal polyp recurrence rate (%)

Timeframe: 1 year and 2.25 years after baseline colonoscopy

Trial details

NCT IDNCT06855355

SponsorKaohsiung Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-31

View on ClinicalTrials.gov More Colorectal Polyp trials